Asian Spectator


The Times

.

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

  • Written by ACN Newswire - Press Releases

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

TOKYO, Apr 1, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku.

On the basis of this agreement, the...

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink StreamEastzlibraryzlibraryzlibrarymatbetbahisfair resmi girişcasibom günceljustin tvjojobetjojobetjojobetPorno siteleri HDPadişahbetGalabetStreamEast1xbettipobet resmi girişjojobetcasino sitelericasibomcasibomPadişahbetGalabetVipparkmarsbahistaraftarium24vippark girismarsbahisbetparkmeritkingdeneme bonusu